CN102333533A - 取代的喹唑啉化合物 - Google Patents

取代的喹唑啉化合物 Download PDF

Info

Publication number
CN102333533A
CN102333533A CN2009801575427A CN200980157542A CN102333533A CN 102333533 A CN102333533 A CN 102333533A CN 2009801575427 A CN2009801575427 A CN 2009801575427A CN 200980157542 A CN200980157542 A CN 200980157542A CN 102333533 A CN102333533 A CN 102333533A
Authority
CN
China
Prior art keywords
phenyl
base
quinazoline
amino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801575427A
Other languages
English (en)
Chinese (zh)
Inventor
卡罗琳·勒里什
埃里克·奥克莱尔
雅克·乐鲁
大卫·N·米德尔米斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fovea Pharmaceuticals SA
Original Assignee
Fovea Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102333533(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals SA filed Critical Fovea Pharmaceuticals SA
Publication of CN102333533A publication Critical patent/CN102333533A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801575427A 2008-12-29 2009-12-18 取代的喹唑啉化合物 Pending CN102333533A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29
EP08360043.7 2008-12-29
PCT/EP2009/067494 WO2010076238A1 (en) 2008-12-29 2009-12-18 Substituted quinazoline compounds

Publications (1)

Publication Number Publication Date
CN102333533A true CN102333533A (zh) 2012-01-25

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801575427A Pending CN102333533A (zh) 2008-12-29 2009-12-18 取代的喹唑啉化合物

Country Status (23)

Country Link
US (1) US8389530B2 (enExample)
EP (1) EP2381943A1 (enExample)
JP (1) JP2012514020A (enExample)
KR (1) KR20110120878A (enExample)
CN (1) CN102333533A (enExample)
AU (1) AU2009334869A1 (enExample)
BR (1) BRPI0924067A2 (enExample)
CA (1) CA2748319A1 (enExample)
CO (1) CO6390105A2 (enExample)
CR (1) CR20110368A (enExample)
DO (1) DOP2011000209A (enExample)
EA (1) EA019110B1 (enExample)
EC (1) ECSP11011204A (enExample)
IL (1) IL213742A0 (enExample)
MA (1) MA32968B1 (enExample)
MX (1) MX2011007064A (enExample)
NI (1) NI201100134A (enExample)
NZ (1) NZ593949A (enExample)
PE (1) PE20120424A1 (enExample)
SG (1) SG172415A1 (enExample)
TN (1) TN2011000319A1 (enExample)
WO (1) WO2010076238A1 (enExample)
ZA (1) ZA201104777B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916759A (zh) * 2020-06-19 2023-04-04 南京红云生物科技有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
BR112017013491A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de pirimidina fundida para o tratamento de hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
NZ733125A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038315A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
WO2006039718A2 (en) * 2004-10-01 2006-04-13 Amgen Inc Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
WO2007117607A2 (en) * 2006-04-06 2007-10-18 Novartis Ag Quinazolines for pdk1 inhibition
EP1878727A1 (en) * 2005-04-28 2008-01-16 Kyowa Hakko Kogyo Co., Ltd. 2-aminoquinazoline derivatives
WO2008079988A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CN1882345A (zh) 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
AU2006227628A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
BRPI0606172A2 (pt) 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038315A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
WO2006039718A2 (en) * 2004-10-01 2006-04-13 Amgen Inc Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
EP1878727A1 (en) * 2005-04-28 2008-01-16 Kyowa Hakko Kogyo Co., Ltd. 2-aminoquinazoline derivatives
WO2007117607A2 (en) * 2006-04-06 2007-10-18 Novartis Ag Quinazolines for pdk1 inhibition
WO2008079988A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIGNE TEUBER HENRIKSEN,ETC: "2-Chloroquinazoline. Synthesis and reactivity of a versatile heterocyclic building block", 《TETRAHEDRON LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916759A (zh) * 2020-06-19 2023-04-04 南京红云生物科技有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Also Published As

Publication number Publication date
SG172415A1 (en) 2011-07-28
PE20120424A1 (es) 2012-05-04
CR20110368A (es) 2011-12-02
MX2011007064A (es) 2012-01-20
MA32968B1 (fr) 2012-01-02
US20120004210A1 (en) 2012-01-05
EP2381943A1 (en) 2011-11-02
JP2012514020A (ja) 2012-06-21
US8389530B2 (en) 2013-03-05
KR20110120878A (ko) 2011-11-04
TN2011000319A1 (en) 2012-12-17
IL213742A0 (en) 2011-07-31
BRPI0924067A2 (pt) 2016-01-26
ECSP11011204A (es) 2011-10-31
WO2010076238A1 (en) 2010-07-08
CA2748319A1 (en) 2010-07-08
NI201100134A (es) 2012-03-06
EA019110B1 (ru) 2014-01-30
DOP2011000209A (es) 2011-09-30
CO6390105A2 (es) 2012-02-29
AU2009334869A2 (en) 2011-09-29
EA201101012A1 (ru) 2012-01-30
ZA201104777B (en) 2012-03-28
NZ593949A (en) 2013-08-30
AU2009334869A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
CN102333533A (zh) 取代的喹唑啉化合物
US20120041195A1 (en) Heterocyclic compounds
CN104903321B (zh) 作为激酶抑制剂的经取代三环苯并咪唑
KR101177729B1 (ko) 벤조트리아졸 키나아제 조절제
JP6753849B2 (ja) 血漿カリクレイン阻害剤としてのｎ−（（ヘタ）アリールメチル）−ヘテロアリール−カルボキサミド化合物
US20130123271A1 (en) Heterocyclic compounds, their preparation and therapeutic application
US20230374143A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss
CN108368127A (zh) 1-取代的1,2,3,4-四氢-1,7-萘啶-8-胺衍生物及其作为ep4受体拮抗剂的用途
WO2019170150A1 (zh) 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
US20090036475A1 (en) Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
KR20140011773A (ko) 이중 저해 활성을 갖는 헤테로고리 유도체
US20070238734A1 (en) Jnk inhibitors
CA2799328C (en) 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
TW202334132A (zh) Ｓａｒｍ１酶活性抑制劑及其應用
AU2011211410B2 (en) [1,2,4] triazolo [1,5-A] pyridines as kinase inhibitors
HK1145493A (en) Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20120125

C20 Patent right or utility model deemed to be abandoned or is abandoned